|
|
Article: ArmaGen Technologies Selects PacificGMP to Manufacture Its Fusion Protein for Phase 1 Clinical Trial.
- Article from:
- Clinical Trials Week
- Article date:
- November 2, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PacificGMP, the leader in single-use bioprocessing for development and manufacturing for its client partners, announced that ArmaGen Technologies has selected it to produce its proprietary protein for a Phase 1 clinical trial. Under the agreement, PacificGMP will use a perfusion process to produce the antibody fusion protein, AGT-190, under cGMP (current good manufacturing practices) standards. Additionally, PacificGMP will perform cGMP cell bank development, a necessary component of clinical material production (see also Fusion Proteins).
"We are delighted to have been selected by ArmaGen to produce their human clinical trial material," said Leigh N. Pierce, ...